Q-omics provides the consensus-scored DCC profile across patient tissues and cancer cell-line models. DCC expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DCC is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, DCC RNA expression shows 12,511 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRP, and TGCT as cancer lineages where DCC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCC survival associations across molecular data types. DCC RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCC RNA expression–survival associations across cancer types. High DCC expression shows unfavorable associations in ACC, but favorable associations in HNSC, BRCA, CESC, SCLC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DCC RNA expression.
This table summarizes DCC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for DCC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCC shows lower tumor expression in KIRP, LUAD, KICH, LUSC, KIRC and BRCA. The KIRP box plot shows higher DCC RNA expression in normal versus tumor tissue (log2 FC = −0.209, t-test p < 0.001).
This table shows molecular features associated with DCC in patient tissues and cancer cell lines. In patient samples, DCC shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DCC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
